FindTrial
Sign In

PF-05212384

DRUG7 trials

Sponsors

Pfizer, Cristiana Sessa, Institut Curie

Conditions

Acute Myeloid Leukemia, in RelapseAdvanced CancerBreast CancerEndometrial CancerEndometrial NeoplasmsHead and Neck (HNSCC)HealthyMetastatic Colorectal Cancer

Phase 1

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
TerminatedNCT01347866
PfizerAdvanced Cancer
Start: 2011-10-31End: 2015-12-31Updated: 2018-10-29
A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
TerminatedNCT01937715
PfizerMetastatic Colorectal Carcinoma
Start: 2014-02-28End: 2015-08-31Updated: 2016-08-18
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
CompletedNCT02069158
Cristiana SessaBreast Cancer, Endometrial Cancer, Head and Neck (HNSCC) +3
Start: 2014-04-30End: 2019-05-31Updated: 2019-05-21
Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers
CompletedNCT02142920
PfizerHealthy
Start: 2014-07-31End: 2014-08-31Updated: 2014-09-04

Phase 2

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
TerminatedNCT01420081
PfizerEndometrial Neoplasms
Start: 2012-01-19End: 2015-12-25Updated: 2019-01-08
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
TerminatedNCT01925274
PfizerMetastatic Colorectal Cancer
Start: 2013-11-15End: 2016-04-06Updated: 2019-01-08
PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)
TerminatedNCT02438761
Institut CurieAcute Myeloid Leukemia, in Relapse, de Novo Acute Myeloid Leukemia at Diagnostic, Therapy-related Acute Myeloid Leukemia and Myelodysplastic Syndrome
Start: 2015-08-31End: 2018-04-23Updated: 2025-09-08

Related Papers

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results
Blood2018-11-2911 citations
Distribution, Metabolism, and Excretion of Gedatolisib in Healthy Male Volunteers After a Single Intravenous Infusion
Clinical Pharmacology in Drug Development2018-09-266 citations
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
2017-12-0178 citations
A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
2016-04-2479 citations
A randomized phase II study (B2151005) of the intravenous phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 plus irinotecan versus cetuximab plus irinotecan in patients with wild-type <i>KRAS</i> metastatic colorectal cancer (mCRC).
Journal of Clinical Oncology2014-05-206 citations
Randomized phase Ib/II study of PF-05212384 plus 5-fluorouracil-leucovorin-irinotecan (FOLFIRI) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer (B2151007; NCT01937715).
Journal of Clinical Oncology2014-05-203 citations